[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fSXP1iyWy0V3_lxhMIKV2B_HMDapyeqSbU1moy8qWE08":8,"$fDbCBctgow9nyEMn6zVnGjSub2J4LYVsvCfOr0VMezNY":55,"$f9WFE5L2dKE0hKDyyQvMXWOLr0SaHJdaCZ15y4HuXZf0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68596,870955,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","荆涛","桓台县人民医院","肝胆外科","副主任医师",3,0,"肝癌局部与仑伐替尼用药全解：射频消融术、TACE及口服靶向药物关键要点","","https://ystcdn.venuertc.com/venue/AI/7a2ec04d-4f13-4467-8dee-9aa12e8cdcb4.jpg","\u003C!-- 仑伐替尼及局部肝癌治疗用药指南：从射频消融到靶向药物的实用分析 BEGIN -->\n\u003Cdiv class=\"enva-wrapper\">\n    \u003Ch1 id=\"material_title\" class=\"enva-title\">肝癌局部与仑伐替尼用药全解：射频消融术、TACE及口服靶向药物关键要点\u003C/h1>\n    \u003Cdiv class=\"enva-lead\">\n        \u003Cp>\n            说到肝癌治疗时，传统的局部消融术和化疗栓塞常与新型靶向药物联用，尤其是仑伐替尼（Lenvatinib），已成为近几年临床应用的重点。其实，这类药物和手术方式在用法、安全性和药物管理上有不少容易忽视的细节。本文会详细梳理：仑伐替尼、射频消融及TACE用药方案的7大核心环节、具体操作步骤和关键注意事项。希望各位能快速抓住重点，安全用药、提升疗效。🌿\n        \u003C/p>\n    \u003C/div>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">1️⃣ 药品成分与剂型选择 👩‍🔬\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect1\">\n            \u003Cul>\n                \u003Cli>\u003Cstrong>仑伐替尼\u003C/strong>：属于多靶点酪氨酸激酶抑制剂，主要以口服胶囊剂型使用。\u003C/li>\n                \u003Cli>\u003Cstrong>射频消融术\u003C/strong>：使用消融设备，涉及麻醉药品短期应用（如丙泊酚、芬太尼等），不长期服药。\u003C/li>\n                \u003Cli>\u003Cstrong>TACE（肝动脉化疗栓塞术）\u003C/strong>：涉及化疗药物如阿霉素或顺铂，与栓塞微球或油脂联合用药，术后无需持续口服。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>正确做法：\u003C/span>\n                \u003Cul>\n                    \u003Cli>明确药品名称及剂型，切勿将仑伐替尼混用或错误当作注射药品。\u003C/li>\n                    \u003Cli>消融术及TACE结束后无需继续相关局部药品使用，术后管理以口服/辅助用药为主。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">2️⃣ 作用机制快速理解 🎯\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect2\">\n            \u003Cp>\n                仑伐替尼通过阻断多种受体酪氨酸激酶（如VEGFR、FGFR等）信号，影响肿瘤血供和生长环境，达到抑制肝内细胞增殖的作用。局部消融术本质是物理破坏，化疗栓塞则通过血管堵塞联合化学药品杀灭靶点细胞。\u003Cbr>\n                \u003Cstrong>临床研究数据显示：\u003C/strong>仑伐替尼中位缓解率可达40%以上，部分受试者3个月内即可评价疗效（Kudo et al., 2018）。\n            \u003C/p>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>需要注意：\u003C/span>\n                \u003Cul>\n                    \u003Cli>仑伐替尼属于靶向口服药，不能替代手术或局部消融。\u003C/li>\n                    \u003Cli>消融及TACE为短时干预，药品主要在术中发挥作用，后续维持治疗主要由口服药品完成。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">3️⃣ 用法用量的关键细节 💊\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect3\">\n            \u003Cul>\n                \u003Cli>\u003Cstrong>仑伐替尼\u003C/strong>用法：应每天一次，于饭后或空腹均可，由专业医生根据体重（如≥60kg或<60kg，常见起始剂量分别为12mg/8mg）个体化调整。不建议随意增减剂量。\u003C/li>\n                \u003Cli>\u003Cstrong>服药体验：\u003C/strong>有位患者在医生指导下每日固定时间服用仑伐替尼，有效控制了药品血药浓度波动。\u003C/li>\n                \u003Cli>应整粒吞服，不可碾碎后口服，以免影响药品释放。\u003C/li>\n                \u003Cli>遇漏服：若当日发现漏服，应及时补服，若接近下次服药时则跳过，不应加倍服用。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>特别提醒：\u003C/span>\n                \u003Cul>\n                    \u003Cli>服药期间慎用葡萄柚汁及含葡萄柚的制品，会干扰药物代谢。\u003C/li>\n                    \u003Cli>如需联合其他口服药品，务必咨询医生是否需分时段服用。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">4️⃣ 药物相互作用浅析 & 避免误区 🤝\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect4\">\n            \u003Cul>\n                \u003Cli>仑伐替尼主要由肝脏CYP3A酶代谢，合用强效酶抑制剂（如酮康唑、红霉素等）或诱导剂（如利福平）会加速药物代谢，影响疗效。\u003C/li>\n                \u003Cli>不建议与某些抗真菌药、抗结核药同时服用，必要时需调整时间间隔或更换药品。\u003C/li>\n                \u003Cli>临床资料表明：仑伐替尼与阿霉素等化疗药品暂未见显著药物相互影响，但应每批联合用药时提前做药学评估。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>正确做法：\u003C/span>\n                \u003Cul>\n                    \u003Cli>记录所有在用药品，定期与医生核查药物清单。\u003C/li>\n                    \u003Cli>避免自行调整用药组合，无论是常见感冒药还是保健品均需告知医生。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">5️⃣ 特殊人群调整与禁忌 📋\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect5\">\n            \u003Cul>\n                \u003Cli>肝功能不全者用药前需个体化评估，部分患者需降低起始剂量，定期监测肝肾功能。\u003C/li>\n                \u003Cli>孕妇及哺乳期妇女禁止使用仑伐替尼，如误用需及时停药并就医。\u003C/li>\n                \u003Cli>年龄较大者或体重过低患者，考虑适度减量，但不得擅自断药。\u003C/li>\n                \u003Cli>有位患者术后因肝硬化，医生调整了仑伐替尼起始剂量，经随访未见明显副作用。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>需要注意：\u003C/span>\n                \u003Cul>\n                    \u003Cli>存在未控制的高血压、严重出血倾向等情况者为仑伐替尼使用禁忌。\u003C/li>\n                    \u003Cli>服药期间需定期检查血压和尿蛋白，防止潜在风险。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">6️⃣ 不良反应与处理方法 🩹\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect6\">\n            \u003Cul>\n                \u003Cli>仑伐替尼常见副作用包括高血压、腹泻、蛋白尿、乏力、食欲减退，发生率约30%-60%（Kudo et al., 2018）。\u003C/li>\n                \u003Cli>局部消融术及TACE术后短时间内可能有低热、恶心、轻微腹痛等短暂反应，通常无需特殊处理。\u003C/li>\n                \u003Cli>出现明显乏力或腹泻时，可酌情减量或暂停用药，必要时联系医生。\u003C/li>\n                \u003Cli>一位患者在仑伐替尼服用第2周时出现轻度食欲减退，经调整饮食并短期减量后缓解。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>正确做法：\u003C/span>\n                \u003Cul>\n                    \u003Cli>任何严重副作用（如持续高血压、明显浮肿、严重腹泻）应立即就医，由医生评估是否调整药品剂量。\u003C/li>\n                    \u003Cli>不推荐自行停药，以免影响整体治疗方案。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section\">\n        \u003Ch2 class=\"enva-subtitle\">7️⃣ 储存条件与有效期 ⏲️\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect7\">\n            \u003Cul>\n                \u003Cli>仑伐替尼胶囊需放置于室温、干燥处（20-25°C），避免阳光直射，勿冷藏。\u003C/li>\n                \u003Cli>开封后药品建议在有效期内使用，勿用过期药；过期胶囊建议送至指定药品回收渠道。\u003C/li>\n                \u003Cli>术后局部器械（如消融针、栓塞颗粒）均为一次性用品，无二次储存需求。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>特别提醒：\u003C/span>\n                \u003Cul>\n                    \u003Cli>药品外包装完好才能保证药效，发现胶囊变色或气味异常请勿使用。\u003C/li>\n                    \u003Cli>家中有小孩应加装安全锁，妥善存放，避免儿童误食。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section enva-cut\">\n        \u003Ch2 class=\"enva-subtitle\">💡 总结要点与实用提醒\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect8\">\n            \u003Cul>\n                \u003Cli>仑伐替尼以口服为主，需每日定时，并严密监控副作用。\u003C/li>\n                \u003Cli>局部消融和TACE为一次性干预，后续以口服药品维持。\u003C/li>\n                \u003Cli>药品用量需遵循医生建议，勿随意调整。\u003C/li>\n                \u003Cli>所有药品的相互作用、储存与不良反应都应提前掌握，养成用药记录习惯。\u003C/li>\n                \u003Cli>遇到不明药品问题及时和医生沟通，家人也要知晓相关药品管理要求。\u003C/li>\n            \u003C/ul>\n            \u003Cdiv class=\"enva-tip\">\n                \u003Cspan>使用仑伐替尼治疗时：\u003C/span>\n                \u003Cul>\n                    \u003Cli>每日定时，体重定量，监测血压和蛋白尿。\u003C/li>\n                    \u003Cli>感觉不适切勿随意停药，优先联系专业人士。\u003C/li>\n                \u003C/ul>\n            \u003C/div>\n        \u003C/div>\n    \u003C/section>\n\n    \u003Csection class=\"enva-section enva-ref\">\n        \u003Ch2 class=\"enva-subtitle\">📚 引用文献\u003C/h2>\n        \u003Cdiv class=\"enva-bg effect9\">\n            \u003Col>\n                \u003Cli>Kudo, M., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. \u003Cem>Lancet\u003C/em>, 391(10126), 1163-1173.\u003C/li>\n                \u003Cli>Ikeda, K., et al. (2017). Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma after first-line therapy. \u003Cem>Hepatology Research\u003C/em>, 47(12), 1140-1147.\u003C/li>\n                \u003Cli>Mazzaferro, V., et al. (2020). Lenvatinib in advanced hepatocellular carcinoma: Real-life experience and review of available data. \u003Cem>World Journal of Gastroenterology\u003C/em>, 26(39), 6099-6110.\u003C/li>\n            \u003C/ol>\n        \u003C/div>\n    \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.enva-wrapper {\n    font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Hiragino Sans GB\", \"WenQuanYi Micro Hei\", sans-serif;\n    max-width: 750px;\n    margin: 36px auto 48px auto;\n    background: #fc;\n    border-radius: 12px;\n    box-shadow: 0 4px 28px rgba(102, 128, 174, 0.08), 0 0px 1px rgba(110, 150, 200, 0.01);\n    overflow: hidden;\n    position: relative;\n    padding: 0;\n}\n.enva-title {\n    font-size: 2.2em;\n    color: #355083;\n    text-align: center;\n    margin-top: 36px;\n    margin-bottom: 16px;\n    padding: 0 20px 12px 20px;\n    letter-spacing: 1px;\n    font-weight: 700;\n    border-bottom: 2px solid #e8ecf3;\n}\n.enva-lead {\n    font-size: 1.12em;\n    color: #30526a;\n    background: linear-gradient(90deg, #f6faff 85%, #e4e8ef 100%);\n    padding: 16px 32px;\n    border-radius: 8px;\n    margin: 24px 32px 28px 32px;\n    box-shadow: 0 2px 8px rgba(220,225,240,0.08);\n}\n.enva-section {\n    margin: 36px 26px;\n    padding-bottom: 22px;\n}\n.enva-subtitle {\n    font-size: 1.5em;\n    font-weight: bold;\n    padding: 8px 12px;\n    margin-bottom: 18px;\n    color: #325177;\n    background: #f5f9ff url(\"data:image/svg+xml,%3Csvg width='200' height='28' xmlns='http://www.w3.org/2000/svg'%3E%3Crect fill='%2391b5ff' fill-opacity='0.07' width='200' height='28'/%3E%3Cellipse fill='%23a3ccd1' fill-opacity='0.14' cx='45' cy='15' rx='40' ry='8'/%3E%3C/svg%3E\") left top;\n    background-repeat: no-repeat;\n    border-left: 4px solid #a8bcec;\n    border-bottom: 1px solid #e8ecf3;\n    border-top-left-radius: 4px;\n    border-top-right-radius: 4px;\n}\n.enva-bg {\n    background: linear-gradient(120deg, #f7fcfe 85%, #eaeff2 100%);\n    border-radius: 8px;\n    padding: 20px 18px 18px 18px;\n    font-size: 1.09em;\n    box-shadow: 0 1px 6px rgba(216,225,240,0.06);\n}\n.effect1 {background: linear-gradient(90deg,#eef8fb 83%,#f7fafb 100%);}\n.effect2 {background: linear-gradient(120deg,#f5faff 80%,#eaf2fe 100%);}\n.effect3 {background: linear-gradient(110deg,#f8fcfa 80%,#f2f6fb 100%);}\n.effect4 {background: linear-gradient(100deg,#f6fafb 75%,#eaeff6 100%);}\n.effect5 {background: linear-gradient(95deg,#fafdfb 80%,#e5f2ee 100%);}\n.effect6 {background: linear-gradient(120deg,#fcf9f5 80%,#f7efeb 100%);}\n.effect7 {background: linear-gradient(120deg,#f9f5fc 80%,#eceaf9 100%);}\n.effect8 {background: linear-gradient(120deg,#f8fbfc 85%,#e4e8ee 100%);}\n.effect9 {background: linear-gradient(120deg,#f8fcff 85%,#eae8ee 100%);}\n.enva-tip {\n    background: #e3f2fd;\n    border: 1px solid #cfdef2;\n    border-radius: 7px;\n    margin: 18px 0 6px 0;\n    padding: 13px 15px 10px 15px;\n    color: #2c415a;\n    font-size: 1.02em;\n    box-shadow: 0 1px 5px rgba(191,209,230,0.08);\n}\n.enva-tip span {\n    font-weight: bold;\n    color: #4768a2;\n    margin-right: 7px;\n    font-size: 1.065em;\n}\n.enva-section ul, .enva-section ol {\n    padding-left: 23px;\n    margin-bottom: 6px;\n}\n.enva-section li {\n    margin: 6px 0;\n    line-height: 1.8;\n}\n.enva-section.enva-cut {\n    border-top: 2px dashed #d0e7fd;\n    padding-top: 18px;\n}\n.enva-section.enva-ref {\n    border-top: 1.6px dotted #c6d4e5;\n    font-size: 1em;\n    padding-top: 12px;\n    margin-bottom: 18px;\n}\n@media (max-width:700px) {\n    .enva-wrapper {margin: 20px 0;max-width: 98%;border-radius: 9px;}\n    .enva-title,.enva-lead{padding-left: 2vw;padding-right: 2vw;}\n    .enva-section {margin: 7vw 1vw;}\n}\n\u003C/style>\n\u003C!-- 仑伐替尼及局部肝癌治疗用药指南 END -->","\u003C!-- 仑伐替尼及局部肝癌治疗用药指南：从射频消融到靶向药物的实用分析 BEGIN -->\n\u003Cdiv class=\"enva-wrapper\">\n    \u003Ch1 id=\"material_title",529,"2025-10-28 00:01:55","肝癌, 仑伐替尼, 射频消融, TACE, 局部治疗, 药物使用, 安全用药, 疗效提升","全面解析肝癌治疗中仑伐替尼及局部治疗方案，帮助患者和医生掌握药物使用细节和注意事项，提升治疗效果，确保安全用药。","2025-11-18 15:15:23",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]